Tempest Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2019
Net Income	-26.26	-41.84	-29.49	-35.71	-28.3	Upgrade
Depreciation & Amortization	0.27	0.39	0.38	0.64	0.37	Upgrade
Stock-Based Compensation	3.12	5.3	2.55	1.56	1.11	Upgrade
Other Operating Activities	1.19	1.51	1.88	1.57	1.48	Upgrade
Change in Accounts Payable	-1.41	1.61	-0.26	0	-0.21	Upgrade
Change in Other Net Operating Assets	-3.72	0.01	-2.41	0.87	-0.4	Upgrade
Operating Cash Flow	-26.82	-33.03	-27.36	-31.07	-25.96	Upgrade
Capital Expenditures	-	-0.44	-0.17	-0.56	-0.14	Upgrade
Other Investing Activities	-	-	-	-	0.04	Upgrade
Investing Cash Flow	-	-0.44	-0.17	-0.56	-0.1	Upgrade
Long-Term Debt Issued	-	-	-	-	15	Upgrade
Long-Term Debt Repaid	-6.43	-4.4	-	-4.74	-	Upgrade
Net Debt Issued (Repaid)	-6.43	-4.4	-	-4.74	15	Upgrade
Issuance of Common Stock	7.38	28.9	35.6	8.86	33.53	Upgrade
Other Financing Activities	3.31	-	-	7.28	10.53	Upgrade
Financing Cash Flow	4.26	24.5	35.6	11.4	59.06	Upgrade
Net Cash Flow	-22.56	-8.96	8.08	-20.23	33.01	Upgrade
Free Cash Flow	-26.82	-33.46	-27.53	-31.63	-26.09	Upgrade
Free Cash Flow Per Share	-6.46	-15.59	-23.21	-35.61	-89.49	Upgrade
Cash Interest Paid	0.19	1.18	1.25	1.54	0.95	Upgrade
Cash Income Tax Paid	0.04	0.05	0.19	0.02	-	Upgrade
Levered Free Cash Flow	-17.59	-19.08	-17.47	-18.33	-16.38	Upgrade
Unlevered Free Cash Flow	-17.46	-18.26	-16.57	-17.32	-15.58	Upgrade
Change in Working Capital	-5.13	1.61	-2.68	0.87	-0.61	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.